Placebo-controlled trial demonstrates oral cyclophosphamide improves lung function and symptoms in scleroderma lung disease, indicating sustained benefits over two years.
One year of oral cyclophosphamide in patients with symptomatic scleroderma-related interstitial lung disease had a significant but modest beneficial effect on lung function, dyspnea, thickening of the skin, and the health-related quality of life. The effects on lung function were maintained through the 24 months of the study.
No takes yet. Share an insight, caveat, or question.
Tashkin et al. (2006) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: